New drug AO-252 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new drug called AO-252 in people with advanced solid tumors, including those that have spread to the brain. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or stop them from growing. About 86 adults whos…
Phase: PHASE1 • Sponsor: A2A Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC